I might be reading the article wrong but I don’t think PharmaCyte was the author. The comparison wasn’t too favorable to our little company and seems like a warning to potential investors.
But as a business model, I would be tickled to see PharmaCyte attain the level of success Amgen has over the last forty years (but, I don’t think I’ll live that long). Amgen started as a penny stock and has grown to see $200 a share (with half as many outstanding shares), and pays dividends!
That would be quite a model for PharmaCyte to follow! Hope it takes significantly less than 40 years. :-D
Good post oldmusky. I for one am most certainly concern now more than usual. You know we all here have our big boy and big girl pants on and handle the truth whether good or bad. Why this ceo keeps playing In the penny stock mentality league is beyond me. This company can really go to new heights. But it’s obvious not until with new management.